ALX Oncology (NASDAQ:ALXO – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($0.1319) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.
ALX Oncology (NASDAQ:ALXO – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts expect ALX Oncology to post ($0.59) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.
ALX Oncology Stock Performance
ALXO opened at $1.36 on Thursday. The company has a market cap of $188.06 million, a P/E ratio of -1.20 and a beta of 0.61. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.82. ALX Oncology has a 52-week low of $0.86 and a 52-week high of $2.66.
Analysts Set New Price Targets
Separately, Weiss Ratings raised shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.60.
Check Out Our Latest Research Report on ALX Oncology
ALX Oncology Company Profile
ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.
ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.
Read More
- Five stocks we like better than ALX Oncology
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
